Inovio Pharmaceuticals Inc. (Nasdaq: INO) reported upbeat preliminary results from a clinical study of its PENNVAX-GP HIV vaccine lifting the stock price $1.55 to close at $8.68.
Inovio Pharmaceuticals reports upbeat study results
May 24, 2017 at 16:51 PM EDT
